Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

AAV Empty/Full Capsid Ratio Analysis for CMC Dossiers

FREQUENTLY ASKED QUESTIONS

AAV Empty/Full Capsid Ratio Analysis for CMC Dossiers

CELL & GENE | RNA | BIOLOGICS

Why is the AAV empty/full capsid ratio a key quality attribute (CQA) for regulatory submissions to agencies like Swissmedic, the EMA, and FDA?

The ratio of genome-containing (“full”) to “empty” AAV capsids directly impacts product potency, safety, and immunogenicity. Regulatory bodies require precise characterization of this ratio as part of the Chemistry, Manufacturing, and Controls (CMC) data package to ensure batch-to-batch consistency and to accurately define the therapeutic dose. An excess of empty capsids can contribute to unnecessary immune responses without providing therapeutic benefit.

What are the primary differences between Analytical Ultracentrifugation (AUC) and Size Exclusion Chromatography with Multi-Angle Light Scattering (SEC-MALS) for this analysis?

AUC and SEC-MALS are orthogonal methods that provide complementary data. AUC separates particles based on their sedimentation coefficient in a centrifugal field, offering high-resolution, matrix-free analysis. SEC-MALS separates particles by their hydrodynamic radius, followed by light scattering detection to determine the absolute molar mass of the eluting species. AUC is often considered a reference method for accuracy, while SEC-MALS provides higher throughput.

How does robust empty/full capsid analysis support an Investigational Medicinal Product Dossier (IMPD) for European submissions?

A well-characterized empty/full capsid ratio is a cornerstone of the IMPD, demonstrating a deep understanding and control over the manufacturing process. Including data from orthogonal methods like AUC and SEC-MALS provides a comprehensive analytical package that de-risks the submission. This level of detail satisfies European regulators’ expectations for product quality and consistency for advanced therapy medicinal products (ATMPs).

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

Proven Intelligence in AAV Vector Analytics.

The characterization of adeno-associated virus (AAV) vector preparations is a foundational component of any successful CMC strategy. For sponsors targeting submissions in Switzerland, the EU, or the US, demonstrating control over product heterogeneity is a requirement. The ratio of empty to full (genome-containing) capsids stands out as a key quality attribute that directly influences both safety and efficacy profiles.

Franklin Biolabs provides high-resolution analytical services to precisely quantify this ratio, employing orthogonal methods to build a robust data package suitable for global regulatory review. Our approach is built on the scientific track record of our core team, which has contributed to a 100% successful IND rate since 2019. While Franklin Biolabs was formally launched in 2024, this history of execution informs every analytical program we undertake.

Orthogonal Methods for Definitive Characterization

A defensible analytical strategy relies on multiple, independent measurements. We utilize two principal techniques for empty/full capsid analysis, ensuring the data is robust enough for IND and IMPD submissions.

  • Analytical Ultracentrifugation (AUC): This technique provides a first-principles measurement of capsid content by separating species based on their unique sedimentation velocities. It is a powerful method for resolving full, partially full, and empty capsids without reliance on column interactions or standard curves.

  • Size Exclusion Chromatography with Multi-Angle Light Scattering (SEC-MALS): SEC-MALS offers a complementary analysis, separating particles based on size and then using light scattering to determine their absolute molar mass. This confirms particle identity and provides quantitative data on the distribution of species within a sample.

This dual-methodology approach aligns with ICH guidelines and provides the comprehensive characterization expected by global health authorities. As one biotech partner noted, our team possesses, “Vast knowledge in all aspects of vector production and analytics.”

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

Impact on Safety and Efficacy

Controlling the empty/full ratio is directly linked to clinical outcomes. An excess of empty capsids can increase the total protein dose administered to a patient, potentially elevating the risk of an unwanted immune response against the capsid itself (PMID: 28323492). This has significant implications for both initial safety and the potential for re-dosing.

The biological activity of an AAV vector is directly dependent on the successful delivery of its genetic payload. A high proportion of full capsids is a prerequisite for achieving therapeutic efficacy. For engineered capsids designed for specific receptor binding, confirming that the therapeutic payload is present in the correctly formed particles is necessary to achieve the intended tissue-specific targeting (PMID: 37199615).

Developing a clear analytical and manufacturing strategy from the outset is a key focus of our scientific consultation, a topic explored in our webinar on initiating successful AAV programs.

Our analytical services provide the definitive data needed to connect the manufactured product to its biological function, de-risking the path to clinical evaluation.

Vector | CMC | Analytics Services

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities